Myeloid/lymphoid neoplasms with eosinophilia and TK fusion genes, version 3.2021

Aaron T. Gerds; Jason Gotlib; Prithviraj Bose; Michael W. Deininger; Andrew Dunbar; Amro Elshoury; Tracy I. George; Ivana Gojo; Krishna Gundabolu; Elizabeth Hexner; Gabriela Hobbs; Tania Jain; Catriona Jamieson; Andrew T. Kuykendall; Brandon J McMahon; Sanjay R. Mohan; Vivian Oehler; Stephen Oh; Animesh Pardanani; Nikolai Podoltsev; Erik Ranheim; Lindsay Rein; Rachel Salit; David S. Snyder; Brady L. Stein; Moshe Talpaz; Swapna Thota; Pankit Vachhani; Martha Wadleigh; Katherine Walsh; Dawn C. Ward; Mary Anne Bergman; Hema Sundar

doi:10.6004/jnccn.2020.0042

Myeloid/lymphoid neoplasms with eosinophilia and TK fusion genes, version 3.2021

Aaron T. Gerds, Jason Gotlib, Prithviraj Bose, Michael W. Deininger, Andrew Dunbar, Amro Elshoury, Tracy I. George, Ivana Gojo, Krishna Gundabolu, Elizabeth Hexner, Gabriela Hobbs, Tania Jain, Catriona Jamieson, Andrew T. Kuykendall, Brandon J McMahon, Sanjay R. Mohan, Vivian Oehler, Stephen Oh, Animesh Pardanani, Nikolai PodoltsevErik Ranheim, Lindsay Rein, Rachel Salit, David S. Snyder, Brady L. Stein, Moshe Talpaz, Swapna Thota, Pankit Vachhani, Martha Wadleigh, Katherine Walsh, Dawn C. Ward, Mary Anne Bergman, Hema Sundar

Medicine, Hematology Oncology Division

Research output: Contribution to journal › Review article › peer-review

11 Scopus citations

Abstract

Eosinophilic disorders and related syndromes represent a heterogeneous group of neoplastic and nonneoplastic conditions, characterized by more eosinophils in the peripheral blood, and may involve eosinophilinduced organ damage. In the WHO classification of myeloid and lymphoid neoplasms, eosinophilic disorders characterized by dysregulated tyrosine kinase (TK) fusion genes are recognized as a new category termed, myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRA, PDGFRB or FGFR1 or with PCM1-JAK2. In addition to these aforementioned TK fusion genes, rearrangements involving FLT3 and ABL1 genes have also been described. These new NCCN Guidelines include recommendations for the diagnosis, staging, and treatment of any one of the myeloid/lymphoid neoplasms with eosinophilia (MLN-Eo) and a TK fusion gene included in the 2017 WHO Classification, as well as MLN-Eo and a FLT3 or ABL1 rearrangement.

Original language	English (US)
Pages (from-to)	1248-1269
Number of pages	22
Journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	18
Issue number	9
DOIs	https://doi.org/10.6004/jnccn.2020.0042
State	Published - Sep 2020

ASJC Scopus subject areas

Oncology

Access to Document

10.6004/jnccn.2020.0042

Cite this

Gerds, A. T., Gotlib, J., Bose, P., Deininger, M. W., Dunbar, A., Elshoury, A., George, T. I., Gojo, I., Gundabolu, K., Hexner, E., Hobbs, G., Jain, T., Jamieson, C., Kuykendall, A. T., McMahon, B. J., Mohan, S. R., Oehler, V., Oh, S., Pardanani, A., ... Sundar, H. (2020). Myeloid/lymphoid neoplasms with eosinophilia and TK fusion genes, version 3.2021. JNCCN Journal of the National Comprehensive Cancer Network, 18(9), 1248-1269. https://doi.org/10.6004/jnccn.2020.0042

@article{a951631b3d5d41a2990782e67262facf,

title = "Myeloid/lymphoid neoplasms with eosinophilia and TK fusion genes, version 3.2021",

abstract = "Eosinophilic disorders and related syndromes represent a heterogeneous group of neoplastic and nonneoplastic conditions, characterized by more eosinophils in the peripheral blood, and may involve eosinophilinduced organ damage. In the WHO classification of myeloid and lymphoid neoplasms, eosinophilic disorders characterized by dysregulated tyrosine kinase (TK) fusion genes are recognized as a new category termed, myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRA, PDGFRB or FGFR1 or with PCM1-JAK2. In addition to these aforementioned TK fusion genes, rearrangements involving FLT3 and ABL1 genes have also been described. These new NCCN Guidelines include recommendations for the diagnosis, staging, and treatment of any one of the myeloid/lymphoid neoplasms with eosinophilia (MLN-Eo) and a TK fusion gene included in the 2017 WHO Classification, as well as MLN-Eo and a FLT3 or ABL1 rearrangement.",

author = "Gerds, {Aaron T.} and Jason Gotlib and Prithviraj Bose and Deininger, {Michael W.} and Andrew Dunbar and Amro Elshoury and George, {Tracy I.} and Ivana Gojo and Krishna Gundabolu and Elizabeth Hexner and Gabriela Hobbs and Tania Jain and Catriona Jamieson and Kuykendall, {Andrew T.} and McMahon, {Brandon J} and Mohan, {Sanjay R.} and Vivian Oehler and Stephen Oh and Animesh Pardanani and Nikolai Podoltsev and Erik Ranheim and Lindsay Rein and Rachel Salit and Snyder, {David S.} and Stein, {Brady L.} and Moshe Talpaz and Swapna Thota and Pankit Vachhani and Martha Wadleigh and Katherine Walsh and Ward, {Dawn C.} and Bergman, {Mary Anne} and Hema Sundar",

year = "2020",

month = sep,

doi = "10.6004/jnccn.2020.0042",

language = "English (US)",

volume = "18",

pages = "1248--1269",

journal = "Journal of the National Comprehensive Cancer Network : JNCCN",

issn = "1540-1405",

publisher = "Cold Spring Publishing LLC",

number = "9",

}

Gerds, AT, Gotlib, J, Bose, P, Deininger, MW, Dunbar, A, Elshoury, A, George, TI, Gojo, I, Gundabolu, K, Hexner, E, Hobbs, G, Jain, T, Jamieson, C, Kuykendall, AT, McMahon, BJ, Mohan, SR, Oehler, V, Oh, S, Pardanani, A, Podoltsev, N, Ranheim, E, Rein, L, Salit, R, Snyder, DS, Stein, BL, Talpaz, M, Thota, S, Vachhani, P, Wadleigh, M, Walsh, K, Ward, DC, Bergman, MA & Sundar, H 2020, 'Myeloid/lymphoid neoplasms with eosinophilia and TK fusion genes, version 3.2021', JNCCN Journal of the National Comprehensive Cancer Network, vol. 18, no. 9, pp. 1248-1269. https://doi.org/10.6004/jnccn.2020.0042

TY - JOUR

T1 - Myeloid/lymphoid neoplasms with eosinophilia and TK fusion genes, version 3.2021

AU - Gerds, Aaron T.

AU - Gotlib, Jason

AU - Bose, Prithviraj

AU - Deininger, Michael W.

AU - Dunbar, Andrew

AU - Elshoury, Amro

AU - George, Tracy I.

AU - Gojo, Ivana

AU - Gundabolu, Krishna

AU - Hexner, Elizabeth

AU - Hobbs, Gabriela

AU - Jain, Tania

AU - Jamieson, Catriona

AU - Kuykendall, Andrew T.

AU - McMahon, Brandon J

AU - Mohan, Sanjay R.

AU - Oehler, Vivian

AU - Oh, Stephen

AU - Pardanani, Animesh

AU - Podoltsev, Nikolai

AU - Ranheim, Erik

AU - Rein, Lindsay

AU - Salit, Rachel

AU - Snyder, David S.

AU - Stein, Brady L.

AU - Talpaz, Moshe

AU - Thota, Swapna

AU - Vachhani, Pankit

AU - Wadleigh, Martha

AU - Walsh, Katherine

AU - Ward, Dawn C.

AU - Bergman, Mary Anne

AU - Sundar, Hema

PY - 2020/9

Y1 - 2020/9

N2 - Eosinophilic disorders and related syndromes represent a heterogeneous group of neoplastic and nonneoplastic conditions, characterized by more eosinophils in the peripheral blood, and may involve eosinophilinduced organ damage. In the WHO classification of myeloid and lymphoid neoplasms, eosinophilic disorders characterized by dysregulated tyrosine kinase (TK) fusion genes are recognized as a new category termed, myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRA, PDGFRB or FGFR1 or with PCM1-JAK2. In addition to these aforementioned TK fusion genes, rearrangements involving FLT3 and ABL1 genes have also been described. These new NCCN Guidelines include recommendations for the diagnosis, staging, and treatment of any one of the myeloid/lymphoid neoplasms with eosinophilia (MLN-Eo) and a TK fusion gene included in the 2017 WHO Classification, as well as MLN-Eo and a FLT3 or ABL1 rearrangement.

AB - Eosinophilic disorders and related syndromes represent a heterogeneous group of neoplastic and nonneoplastic conditions, characterized by more eosinophils in the peripheral blood, and may involve eosinophilinduced organ damage. In the WHO classification of myeloid and lymphoid neoplasms, eosinophilic disorders characterized by dysregulated tyrosine kinase (TK) fusion genes are recognized as a new category termed, myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRA, PDGFRB or FGFR1 or with PCM1-JAK2. In addition to these aforementioned TK fusion genes, rearrangements involving FLT3 and ABL1 genes have also been described. These new NCCN Guidelines include recommendations for the diagnosis, staging, and treatment of any one of the myeloid/lymphoid neoplasms with eosinophilia (MLN-Eo) and a TK fusion gene included in the 2017 WHO Classification, as well as MLN-Eo and a FLT3 or ABL1 rearrangement.

UR - http://www.scopus.com/inward/record.url?scp=85090505761&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85090505761&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2020.0042

DO - 10.6004/jnccn.2020.0042

M3 - Review article

C2 - 32886902

AN - SCOPUS:85090505761

SN - 1540-1405

VL - 18

SP - 1248

EP - 1269

JO - Journal of the National Comprehensive Cancer Network : JNCCN

JF - Journal of the National Comprehensive Cancer Network : JNCCN

IS - 9

ER -

Myeloid/lymphoid neoplasms with eosinophilia and TK fusion genes, version 3.2021

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this